Review decision
Decision to conduct a review of the guidance for tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
Tafamidis was not recommended within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy as part of the original evaluation (TA696) in May 2021.
A major uncertainty in the original evaluation was the long-term overall survival estimates. Further follow up data published since the original evaluation indicates that survival is improved with tafamidis for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), to a greater extent than considered during the original evaluation.
Therefore, NICE will review TA696.
This page was last updated: